Target Name: CDH18
NCBI ID: G1016
Review Report on CDH18 Target / Biomarker Content of Review Report on CDH18 Target / Biomarker
CDH18
Other Name(s): Cadherin-like 24 | Cadherin 18, transcript variant 2 | Cadherin 18, type 2 | cadherin-like 24 | OTTHUMP00000221000 | CDH14 | CDH24 | CDH18 variant 2 | Cadherin-14 | Cadherin 18, transcript variant 1 | Cadherin 14 | Ey-cadherin | OTTHUMP00000220999 | ey-cadherin | OTTHUMP00000220998 | cadherin 18 | Cadherin-18 (isoform 1) | OTTHUMP00000221002 | CAD18_HUMAN | CDH14L | OTTHUMP00000221001 | Cadherin-18 | cadherin-14 | Cadherin-18 (isoform 2) | Cadherin 18, type 2, transcript variant 1 | OTTHUMP00000115690 | cadherin 18, type 2 | CDH18 variant 1

CDH18: A Potential Drug Target and Biomarker for the Treatment of Connective Tissue Damage

Chronic diseases such as diabetes, rheumatoid arthritis, and cancer can cause significant damage to the connective tissue, leading to pain, stiffness, and loss of function. Connective tissue is a complex network of cells and fibers that provide support, structure, and function to various organs and tissues throughout the body. These diseases can result in the loss of normal movement, flexibility, and range of motion, which can have a significant impact on an individual's quality of life.

CDH18 is a protein that has been identified as a potential drug target and biomarker for the treatment of connective tissue damage. In this article, we will discuss the structure, function, and potential therapeutic applications of CDH18, as well as its potential as a biomarker for monitoring disease progression.

Structure and Function

CDH18 is a 19-kDa protein that is expressed in various tissues, including tendons, muscles, blood vessels, and organs. It is composed of a unique alternating sequence of 14 non-overlapping exons (1-14, 16-20) and a variable-length variable exon (21) that is unique to each individual. CDH18 is expressed in a variety of tissues and has been shown to participate in various physiological processes, including cell signaling, cytoskeletal organization, and tissue repair.

One of the most significant functions of CDH18 is its role in the regulation of tendon and muscle dynamics. CDH18 has been shown to play a critical role in the regulation of tendon growth and repair, as well as muscle tone and movement. It is also involved in the regulation of cell signaling, including the regulation of cytoskeletal organization and the control of muscle contractions.

Potential Therapeutic Applications

CDH18 has been identified as a potential drug target for the treatment of connective tissue damage due to its involvement in various physiological processes that are important for tissue repair and regeneration. Several studies have shown that inhibiting the activity of CDH18 has the potential to improve tissue repair and regeneration in individuals with connective tissue injuries or diseases.

One of the primary targets for CDH18 is the regulation of tendon and muscle dynamics. The loss of tendon and muscle mass is a common complication in diseases such as diabetes, rheumatoid arthritis, and cancer. CDH18 has been shown to play a critical role in regulating tendon and muscle growth and repair, and inhibiting its activity has been shown to improve tissue repair and regeneration in individuals with these conditions.

In addition to its role in tendon and muscle dynamics, CDH18 is also involved in the regulation of cell signaling. Its expression has been shown to be regulated by various signaling pathways, including TGF-β, Wnt, and NF-kappa-B. Therefore, it is possible that CDH18 may also be a useful biomarker for monitoring disease progression and evaluating the efficacy of therapeutic interventions.

Biomarker Potential

CDH18 has the potential to serve as a biomarker for a variety of connective tissue injuries and diseases. Since its expression is regulated by various signaling pathways, its levels may be affected by a range of factors, including inflammation, fibrosis, and muscle damage. Therefore, measuring the levels of CDH18 in tissues or fluids, such as synovial fluid or muscle biopsy samples, may provide valuable information about the severity and extent of connective tissue damage.

In addition to its potential as a biomarker, CDH18 may also serve as a drug target for the treatment of connective tissue damage. Its involvement in various physiological processes, including cell signaling and tissue repair, makes it a potential target for small molecules that can modulate its activity.

Conclusion

CDH18 is a protein that has been identified as a potential drug target and biomarker for the treatment of connective tissue damage. Its structure and function, as well as its potential as a biomarker and target for small molecules, make it an attractive candidate for further research. Further studies are needed to fully understand its role in the regulation of tendon and muscle dynamics, as well as its potential as a biomarker for disease progression and therapeutic interventions.

Protein Name: Cadherin 18

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types

The "CDH18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4 | CDY1 | CDY1B | CDY2A | CDYL | CDYL2 | CEACAM1 | CEACAM16